GC
CRSP icon

Guggenheim Capital’s CRISPR Therapeutics CRSP Stock Holding History

Guggenheim Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.94M Sell
35,490
-191
-0.5% -$10.1K 0.01% 748
2026
Q1 		$1.7M Sell
35,681
-21,340
-37% -$1.13M 0.01% 768
2025
Q4 		$2.99M Sell
57,021
-440
-0.8% -$26.4K 0.02% 564
2025
Q3 		$3.72M Sell
57,461
-1,027
-2% -$59K 0.03% 519
2025
Q2 		$2.84M Sell
58,488
-37,778
-39% -$1.46M 0.02% 556
2025
Q1 		$3.28M Buy
96,266
+9,065
+10% +$384K 0.03% 523
2024
Q4 		$3.43M Sell
87,201
-670
-0.8% -$31.6K 0.03% 518
2024
Q3 		$4.13M Buy
87,871
+34,518
+65% +$1.75M 0.03% 592
2024
Q2 		$2.88M Buy
53,353
+3,385
+7% +$196K 0.02% 697
2024
Q1 		$3.41M Buy
49,968
+14,128
+39% +$1.01M 0.02% 692
2023
Q4 		$2.24M Sell
35,840
-14,312
-29% -$791K 0.02% 798
2023
Q3 		$2.28M Sell
50,152
-19,313
-28% -$997K 0.02% 766
2023
Q2 		$3.9M Sell
69,465
-5,550
-7% -$315K 0.03% 609
2023
Q1 		$3.39M Sell
75,015
-7,037
-9% -$342K 0.03% 657
2022
Q4 		$3.34M Buy
82,052
+4,403
+6% +$234K 0.03% 670
2022
Q3 		$5.07M Buy
77,649
+4,196
+6% +$304K 0.05% 500
2022
Q2 		$4.46M Sell
73,453
-2,300
-3% -$135K 0.04% 596
2022
Q1 		$4.75M Sell
75,753
-10,186
-12% -$640K 0.03% 673
2021
Q4 		$6.51M Buy
85,939
+20,566
+31% +$1.8M 0.03% 581
2021
Q3 		$7.32M Buy
65,373
+33,651
+106% +$4.23M 0.04% 504
2021
Q2 		$5.14M Buy
31,722
+352
+1% +$42.8K 0.03% 670
2021
Q1 		$3.82M Buy
31,370
+12,539
+67% +$1.89M 0.03% 738
2020
Q4 		$2.88M Buy
+18,831
New +$2.23M 0.02% 808

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Guggenheim Capital's CRSP Position: Q2 2026 in Review

Guggenheim Capital reduced its CRISPR Therapeutics (CRSP) stake by 0.54% in Q2 2026, selling an estimated $10.1K and leaving 35,490 shares worth $1.94M. The position accounts for 0.01% of the portfolio, ranked #748.

Guggenheim Capital first reported a position in CRSP in Q4 2020 and has held it in 23 quarters since. The position peaked at $7.32M in Q3 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Guggenheim Capital held 35,490 shares of CRISPR Therapeutics worth $1.94M as of Q2 2026.
  • Guggenheim Capital sold 191 CRISPR Therapeutics shares in Q2 2026, an estimated $10.1K.
  • CRISPR Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #748 holding.
  • Guggenheim Capital first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Guggenheim Capital's CRISPR Therapeutics position peaked at $7.32M in Q3 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.